RecruitingPhase 2NCT07149207

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors


Sponsor

Medical University of South Carolina

Enrollment

30 participants

Start Date

Jun 15, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is for adult patients with head and neck cancer who are at risk of recurrence. The purpose of this study is to evaluate whether the use of Indocyanine Green (ICG) dye allows for better identification of tumor tissue during surgical procedures. Participation will include standard of care visits along with administration of ICG dye and imaging during surgery. Participation in this study will last approximately 6 weeks.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Adult subjects at least 18 years of age.
  • Subjects presenting with squamous cell carcinoma of mucosal origin and are at risk for recurrence.
  • Good operative candidate as determined by the treating physician and/or multidisciplinary team.
  • Subject capable of giving informed consent and participating in the process of consent.
  • A WOCBP must be willing and able to use highly effective contraception from the time of informed consent throughout the study period. Acceptable forms of birth control include hormonal contraceptives (such as birth control pills, skin patch, vaginal ring, injection, and/or implant), intrauterine devices (IUDs), and barrier devices (such as condoms, diaphragm, cervical cap, and sponge).

Exclusion Criteria10

  • Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study.
  • A WOCBP who has had a positive urine or serum pregnancy test at the time of screening unless:
  • they are menopausal defined by not having a menstrual cycle within the last 12 consecutive months or
  • they have had a hysterectomy.
  • Known allergy to iodides or shellfish.
  • Inadequate organ function at time of screening as defined below:
  • a. Hepatic
  • Total bilirubin >2 x IULN. Participants with a history of Gilbert's disease must have total bilirubin <3mg/dL.
  • AST (SGOT) and ALT (SPGT) >3 x IULN.
  • Currently incarcerated individuals

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIndocyanine Green (ICG)

Dose: 5 mg/kg IV injection prior to surgery


Locations(1)

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07149207


Related Trials